Rebalancing haemostasis with marstacimab - an discussion about the BASIS trial
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Rebalancing haemostasis with marstacimab - an discussion about the BASIS trial
-
Narrado por:
-
De:
On this episode, Pip and Rich discuss the BASIS trial which investigated the efficacy of the rebalancing agent marstacimab in people living with haemophilia. Marstacimab is an inhibitor of tissue factor pathway inhibitor (TFPI) and works by tipping the balance of clotting towards coagulation and away from bleeding. The trial showed that marstacimab works but is not randomised and there are some very interesting critical appraisal points in here even if you are not hugely interested in haemophilia.
Matino et al. Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. Blood (2025) 146 (14): 1654–1663.
Want a free monthly newsletter on medical haematology? Sign up at www.dontjustreadtheabstract.com.
Hosted on Acast. See acast.com/privacy for more information.